Sign In
Buy SPRO
$2.80
-0.0300 (-1.06%)
At Close: Jun 03, 2026
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
08:00am, Friday, 05'th Feb 2021
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:17pm, Friday, 29'th Jan 2021
CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy?
07:32am, Tuesday, 26'th Jan 2021
Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr
08:00am, Thursday, 21'st Jan 2021
CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero: Tebipenem HBr's H2 2021 NDA, SPR720's Phase 2a Data Release And More
11:26pm, Wednesday, 13'th Jan 2021
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for high unmet need areas involving multi-drug-resistant bacterial infections and rare diseases. Spero is r
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer
08:00am, Thursday, 17'th Dec 2020
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics Added to the NASDAQ Biotechnology Index
08:30am, Wednesday, 16'th Dec 2020
CAMBRIDGE, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
CAMBRIDGE, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:01pm, Monday, 30'th Nov 2020
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics to Present at the Evercore ISI HealthCONx Conference on December 3, 2020
09:09am, Monday, 30'th Nov 2020
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript
09:38pm, Saturday, 07'th Nov 2020
Spero Therapeutics' (SPRO) CEO Ankit Mahadevia on Q3 2020 Results - Earnings Call Transcript
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:32am, Tuesday, 03'rd Nov 2020
CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializ
5 Healthcare Stocks the Experts at Aquilo Capital Management Are Buying (1 Has Gained 88% This Month)
05:28pm, Monday, 26'th Oct 2020
Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise i
